TMCnet News
Sanofi's emerging oncology pipeline highlighted at the AACR Virtual Annual Meeting IIBRIDGEWATER, N.J., June 15, 2020 /PRNewswire/ -- Preclinical data for Sanofi's investigational compounds in breast, lung, multiple myeloma and other cancers will be featured at the American Academy of Cancer Research (AACR) Virtual Annual Meeting II on June 22-24. The results that will be presented underscore the Company's commitment to transforming scientific knowledge and advances in innovative oncology therapies. "We believe the innovation and efforts we are driving in oncology have the potential to make a significant difference in the lives of people living with cancer," said Yong Jun Liu, Global Head of Research, Senior Vice President R&D at Sanofi. "Preclinical data presented at this year's AACR Virtual Meeting II showcase the depth of our pipeline and support the continued exploration of our investigational assets that reflect some of the most cutting-edge scientific technologies and platforms in oncology." Preclinical data show anti-tumor activity and support further research across a range of solid tumors, including evolving evidence in breast and lung cancers Sanofi continues to embrace a variety of technological approaches to address some of the hardest-to-treat forms of cancer, including breast and lung cancer. Abstract 3452: Pre-clinical development of next generation Selective Estrogen Receptor Degrader – SAR439859 (Dr. Fangxian Sun, Sr.; Tuesday, June 23: Virtual Minisymposium Session, 10:20-10:30 AM) SAR439859 (SERD '859) is a oral endocrine backbone therapy in hormone receptor positive (HR+) breast cancer that selectively binds to estrogen receptors in breast cancer cells to block signaling and trigger their degradation. Breast cancer is the second most common form of cancer worldwide, with an estimated 70-80% of breast cancers being HR+.
Abstract 561/16: Pre-clinical efficacy data for the anti-CEACAM5-DM4 ADC SAR408701 supports further development in lung and gastro-intestinal cancers (Dr. Stephanie Decary; Monday, June 22: Poster Display, 9:00 AM-6:00 PM) SAR408701 (SAR '701) is Sanofi's potential first-in-class antibody-drug conjugate targeting CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5), a cell-surface glycoprotein that is highly expressed in non-squamous non-small cell lung cancers (NSCLC). Approximately 20-30% of lung cancers have a high expression of CEACAM5.
Abstract 1943/10: SHP2 inhibition as the backbone of targeted therapy combinations for the treatment of cancers driven by oncogenic mutations in the RAS pathway (Dr. Jacqueline Smith; Monday, June 22: Poster Display, 9:00AM-6:00PM) SAR442720 (RMC-4630) is an investigational inhibitor of the cellular enzyme SHP2 developed jointly by Sanofi and Revolution Medicines. Inhibitors of SHP2 are designed to reduce cell growth signaling in the RAS-MAP kinase pathway that is frequently overactive in human cancers, like NSCLC.
Preclinical data add to growing body of evidence supporting Sarclisa (isatuximab-irfc) in multiple myeloma and other blood cancers Sanofi is committed to investigating new treatments for patients with multiple myeloma, a difficult-to-treat blood cancer, who often need multiple lines of therapy. Despite available treatments, multiple myeloma remains an incurable malignancy and is associated with significant patient burden. Abstract 5179/5: Isatuximab based combinations induce potent tumor growth inhibition in pre-clinical models of multiple myeloma and acute lymphocytic leukemia (Dr. Chen Zhu; Monday, June 22: Poster Display, 9:00 AM-6:00 PM) Sarclisa is a monoclonal antibody that binds to the CD38 receptor on multiple myeloma cells. It is currently approved for use in the U.S. and EU in combination with pomalidomide and dexamethasone for the treatment of certain adults who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
Early science: new approaches in blood cancer research Abstract 2266/1: SAR442085, a next generation anti-CD38 antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC) against multiple myeloma (Dr. Angela Virone-Oddos; Monday, June 22: Poster Display, 9:00 AM-6:00 PM) Current anti-CD38 treatments in combination with standard treatments represent a major advancement in the treatment of patients with relapsed and refractory multiple myeloma, but unmet needs remain. Sanofi scientists investigating a next-generation anti-CD38 antibody SAR442085 for the treatment of multiple myeloma will present preclinical data at the meeting.
Abstract 5641/2: CD28 expression on multiple myeloma cells enhances the cytotoxic activity of CD38/CD28xCD3 trispecific T-cell engager (Dr. Nizar El-Murr; Monday, June 22: Poster Display, 9:00 AM-6:00 PM) Sanofi scientists are also investigating the trispecific T-cell engager SAR442257 (CD38/CD28xCD3) as a potential treatment for multiple myeloma.
The clinical significance of the preclinical findings relating to SERD '859, SAR '701, SAR442720, Sarclisa, SAR442085 and SAR442257 described above are currently under investigation. About Sarclisa Sarclisa is a monoclonal antibody that binds to a specific epitope on the CD38 receptor on MM cells. It is designed to work through multiple mechanisms of action including programmed tumor cell death (apoptosis) and immunomodulatory activity. CD38 is highly and uniformly expressed on the surface of MM cells, making it a potential target for antibody-based therapeutics such as Sarclisa. Sarclisa is approved in the EU, U.S., Switzerland, Canada and Australia in combination with pom-dex for the treatment of certain adults with relapsed refractory MM. In the U.S., the generic name for Sarclisa is isatuximab-irfc, with irfc as the suffix designated in accordance with Nonproprietary Naming of Biological Products Guidance for Industry issued by the U.S. Food and Drug Administration. Sarclisa continues to be evaluated in multiple ongoing Phase 3 clinical trials in combination with current standard treatments across the MM treatment continuum. It is also under investigation for the treatment of other hematologic malignancies and solid tumors. The safety and efficacy of these additional uses have not been evaluated by any regulatory authority. For more information on Sarclisa clinical trials please visit www.clinicaltrials.gov. IMPORTANT SAFETY INFORMATION AND INDICATION FOR U.S. PATIENTS What is SARCLISA? SARCLISA is a prescription medicine used in combination with pomalidomide and dexamethasone to treat adults who have received at least 2 prior therapies, including lenalidomide and a proteasome inhibitor, to treat multiple myeloma. It is not known if SARCLISA is safe and effective in children. Do not receive SARCLISA if you have a history of severe allergic reaction to isatuximab-irfc or any of the ingredients in SARCLISA (see the list of ingredients in full Prescribing Information). Before receiving SARCLISA, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider right away if you think you are pregnant or become pregnant during treatment with SARCLISA.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. How will I receive SARCLISA?
Your healthcare provider will decide how long you should receive SARCLISA.
What are the possible side effects of SARCLISA? SARCLISA may cause serious side effects, including:
Tell your healthcare provider right away if you develop any of the following symptoms of infusion reaction during or within 24 hours after an infusion of SARCLISA:
Your healthcare provider will check your blood cell counts during treatment with SARCLISA. Your healthcare provider may prescribe an antibiotic or antiviral medicine to help prevent infection, or a medicine to help increase your white blood cell counts during treatment with SARCLISA. Tell your healthcare provider right away if you develop any fever or symptoms of infection during treatment with SARCLISA.
These are not all the possible side effects of SARCLISA. For more information, ask your healthcare provider or pharmacist. Please see full Prescribing Information, including Patient Information. About Sanofi Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe. Sanofi, Empowering Life
Sanofi Forward-Looking Statements Source: Sanofi (EURONEXT: SAN) (NASDAQ: SNY). View original content to download multimedia:http://www.prnewswire.com/news-releases/sanofis-emerging-oncology-pipeline-highlighted-at-the-aacr-virtual-annual-meeting-ii-301076674.html SOURCE Sanofi |